These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Dose-response relations in phototoxicity due to 8-methoxypsoralen and UV-A in man. Ljunggren B; Bjellerup M; Carter DM J Invest Dermatol; 1981 Feb; 76(2):73-5. PubMed ID: 7462679 [TBL] [Abstract][Full Text] [Related]
5. Photochemotherapy of psoriasis with methoxsalen and longwave ultraviolet light (PUVA). Bond CA; Grant K; Boh L Am J Hosp Pharm; 1981 Jul; 38(7):990-5. PubMed ID: 7020414 [TBL] [Abstract][Full Text] [Related]
7. Lenticular psoralen photoproducts and cataracts of a PUVA-treated psoriatic patient. Woo TY; Wong RC; Wong JM; Anderson TF; Lerman S Arch Dermatol; 1985 Oct; 121(10):1307-8. PubMed ID: 4037825 [TBL] [Abstract][Full Text] [Related]
8. Photochemotherapy in psoriasis-clinical response and 8-MOP plasma concentrations at two dose levels. Andrew E; Nilsen A; Thune P; Wiik I Clin Exp Dermatol; 1981 Nov; 6(6):591-600. PubMed ID: 7042134 [No Abstract] [Full Text] [Related]
9. Bath-5-methoxypsoralen-UVA therapy for psoriasis. Calzavara-Pinton PG; Zane C; Carlino A; De Panfilis G J Am Acad Dermatol; 1997 Jun; 36(6 Pt 1):945-9. PubMed ID: 9204060 [TBL] [Abstract][Full Text] [Related]
10. Phototesting and phototoxic side effects in bath PUVA. Calzavara-Pinton PG; Ortel B; Carlino AM; Honigsmann H; De Panfilis G J Am Acad Dermatol; 1993 Apr; 28(4):657-9. PubMed ID: 8463475 [No Abstract] [Full Text] [Related]
12. Microenema of 8-methoxypsoralen in photochemotherapy of psoriasis. Siddiqui AH; Stolk L; Korthals Altes-Levij van Vinninghe HR; Kammeijer A; Cormane RH Arch Dermatol Res; 1982; 273(3-4):219-23. PubMed ID: 7165351 [TBL] [Abstract][Full Text] [Related]
13. Skin pigmentation as a predictor of minimal phototoxic dose after oral methoxsalen. Bech-Thomsen N; Angelo HR; Wulf HC Arch Dermatol; 1994 Apr; 130(4):464-8. PubMed ID: 8166483 [TBL] [Abstract][Full Text] [Related]
14. Malignant melanoma in a patient with severe psoriasis treated by oral methoxsalen photochemotherapy. Frenk E Dermatologica; 1983; 167(3):152-4. PubMed ID: 6414855 [No Abstract] [Full Text] [Related]
15. Photochemotherapy of psoriasis: risk:benefit ratios. Bickers DR J Am Acad Dermatol; 1981 Jan; 4(1):90-3. PubMed ID: 7204695 [No Abstract] [Full Text] [Related]
16. 5-Methoxy psoralen, etretinate, and UVA for psoriasis. Lane-Brown M Int J Dermatol; 1987 Dec; 26(10):655-9. PubMed ID: 3429102 [TBL] [Abstract][Full Text] [Related]
17. Combination therapy of oral methoxypsoralen: photochemotherapy (PUVA) and an aromatic retinoid (etretinate, tigason) in the treatment of psoriasis. Thirumoorthy T; Tham SN; Tan YC J Dermatol; 1986 Apr; 13(2):132-6. PubMed ID: 3531270 [No Abstract] [Full Text] [Related]
18. 8-Methoxypsoralen plasma levels and phototoxic effect. De Bersaques J; Monbaliu J; Belpaire F; Bogaert M Photodermatol; 1984 Apr; 1(2):79-84. PubMed ID: 6531285 [TBL] [Abstract][Full Text] [Related]
19. [8-Methoxypsoralen (8-MOP)-a new galenic form and its relation to 8-MOP serum levels (author's transl)]. Nitsche V; Raff M; Bardach H Arch Dermatol Res; 1981; 271(1):11-7. PubMed ID: 7294879 [TBL] [Abstract][Full Text] [Related]
20. Acute myelomonocytic leukaemia developing in a patient with psoriasis treated with oral 8-methoxypsoralen and longwave ultraviolet light. Freeman K; Warin AP Clin Exp Dermatol; 1985 Mar; 10(2):144-6. PubMed ID: 3856495 [No Abstract] [Full Text] [Related] [Next] [New Search]